The new agent, densoumab, has been priced competitively with these two agents. As drug patents expire, the horizon for osteoporosis prescribing is likely to change again. In summary, most specialists feel that it is a combination of the varying thresholds for initiation with different osteoporosis therapies, and the

lack of accommodation of FRAX-listed risk factors that has made the NICE guidance least amenable to use in clinical practice. Physicians struggle to interpret these differing thresholds for therapy, selleck chemicals and patient groups are understandably vocal about the idea that a woman who is deemed eligible for alendronate therapy, but is unable to tolerate it, will have to wait for her disease to deteriorate before another therapy becomes available to her. The physician also struggles to find guidance for treatment of a woman with a prior fragility fracture but whose bone density T score is above −2.5 SD. The inclusion of FRAX on bone density printouts, and most recently, its appearance as an i-Phone application, is a marker of the readiness with which it has been taken up by the osteoporosis community, and it is to be hoped that as we work Elafibranor concentration toward https://www.selleckchem.com/products/Liproxstatin-1.html greater

translatability between FRAX and NICE, we are about to enter a dawn of more effective policy for prevention and treatment. References 1. National Institute for Health and Clinical Excellence (2010) Final appraisal determination 161. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London, December 2010 2. National Institute for Health and Clinical Excellence (2010) Final appraisal determination160. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London, December 2010 3. Royal College of Physicians (1999) Osteoporosis:

clinical guidelines for the prevention and treatment. Phosphoglycerate kinase Royal College of Physicians, London 4. Royal College of Physicians and Bone and Tooth Society of Great Britain (2000) Update on pharmacological interventions and an algorithm for management. Royal College of Physicians, London 5. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M, National Osteoporosis Guideline Group (NOGG) (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108PubMedCrossRef 6. Kanis JA, McCloskey EV, Jonsson B et al (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Archives of Osteoporosis. doi:10.​1007/​s11657-010-0045-5 7.